Annovis Bio Inc. has achieved a notable milestone with the issuance of a U.S. patent for its leading drug candidate, buntanetap, which is being investigated for the treatment of acute traumatic brain injuries

Spinogenix, Inc., a biopharmaceutical company at the forefront of developing innovative therapies to restore synaptic function, has announced the start of enrollment for its Phase 2 clinical trial of SPG601. This study aims to assess the drug's

Diamyd Medical has received encouraging feedback from the U.S. Food and Drug Administration concerning an Accelerated Approval pathway for its immunotherapy, Diamyd®, designed for Stage 3 Type 1 Diabetes patients with the HLA DR3-DQ2 genotype.

Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to gain approval for SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults with treatment-resistant depression

Certa Therapeutics, a biotechnology company developing precision therapies for inflammatory and fibrotic diseases, has been granted Orphan Drug Designation by the European Medicines Agency

Many pharmaceuticals used in the U.S. depend on ingredients sourced from overseas, which can create challenges during supply chain disruptions or shortages, as demonstrated during the COVID-19 pandemic

Rona Therapeutics, a leading clinical-stage company specializing in nucleic acid drug research and development, has secured $35 million in Series A+ funding. This round was spearheaded by LongRiver Investments

Today, Myogenica, a startup from the University of Minnesota, announced that the U.S. Food and Drug Administration has approved their Investigational New Drug application for MyoPAXon. This product, derived from induced pluripotent stem cells

Scilex Holding Company has announced a Memorandum of Understanding for a collaboration agreement with ACEA, a China-based company focused on innovative treatments for high unmet needs.

Cardurion Pharmaceuticals, a biotechnology company in the clinical stage, has announced a successful Series B financing round raising $260 million. Leading the round was Ascenta Capital, joined by new investors